The latest Investing Matters Podcast with Jean Roche, Co-Manager of Schroder UK Mid Cap Investment Trust has just been released. Listen here.
London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
FYI
https://www.linkedin.com/company/launch-diagnostics/
Launch Diagnostics LimitedLaunch Diagnostics Limited
1,678 followers1,678 followers
2d • Edited • 2 days ago
On the 4th April 2024 the Medicines and Healthcare products Regulatory Agency (MHRA) approved the combined antibiotic cefepime/enmetazobactam (brand name Exblifep) to treat adult patients with complicated infections of the urinary tract and certain types of pneumonia.
Enmetazobactam blocks the action of beta-lactamases, allowing cefepime to act against bacteria that would otherwise be resistant.
We are pleased to announce the addition of cefepime-enmetazobactam to the Liofilchem MTS (MIC Test Strip) range.
Currently available as RUO device.
Launch Diagnostics is the exclusive distributor of Liofilchem's portfolio in the UK.
For all your AMR testing solutions, head over to our website: www.launchdiagnostics.com, or contact enquiries@launchdiagnostics.com
hashtag#microbiology hashtag#antimicrobialstewardship hashtag#antimicrobialresistance
hashtag#AMR hashtag#NHS hashtag#antibiotics hashtag#antimicrobials hashtag#patientcare
FYI :
"Launch Diagnostics LimitedLaunch Diagnostics Limited
1,692 followers1,692 followers
55m • 55 minutes ago
The Clonit Quanty assays from Launch Diagnostics Ltd for transplant related pathogens provide accurate quantitation of viruses such as Adenovirus, CMV, EBV, BKV, HHV6 and many more. These assays provide precise and sensitive measurement of viral loads, crucial for monitoring disease progression and treatment efficacy in post transplant patients.
Their high sensitivity enables the detection of even low viral concentrations, facilitating early intervention and improved patient outcomes. Moreover, the assays' quantitative nature allows for precise tracking of viral loads over time, aiding clinicians in making informed decisions regarding therapeutic strategies.
The assays are compatible with many extraction and PCR platforms which you may already have available, allowing these systems to be fully utilised. Many laboratories currently send some or all of these assays to reference labs, and repatriation can offer increased control, decreased turnaround time and cost savings.
For more information on the Clonit quality PCR’s, please visit:
https://www.launchdiagnostics.com/product/clonit-transplant-pcrs/
https://www.launchdiagnostics.com/manufacturer/clonit/
https://lnkd.in/eGZ3ZyS7"
Clonit use a number of distributors world wide : LD cover UK-France -Benelux :
https://www.clonit.it/en/world-wide-distributors/
Good Morning : LD being proactive
https://www.launchdiagnostics.com/product/crypto-giardia-combi-eia/
https://www.linkedin.com/feed/update/urn:li:activity:7196878794434007042/
----------
Outbreak Alert: Cryptosporidium in Brixham Water Supply
Residents in parts of Brixham have been advised to boil their drinking water following the confirmation of 22 cases of cryptosporidiosis in the area.
South West Water has detected small traces of the parasite cryptosporidium in the water supply in Devon. As this situation evolves, the risk of further cases remains if the contamination continues.
At Launch Diagnostics, we understand the urgency and importance of addressing waterborne diseases like cryptosporidiosis promptly and accurately.
Our Crypto ELISA kits provide a reliable solution for detecting cryptosporidium, helping to identify and manage outbreaks effectively.
In these challenging times, accurate diagnostics are crucial.
For more information on our Cryptosporidium ELISA kits and how we can support healthcare providers and laboratories please visit our website or contact our team directly.
https://lnkd.in/eBjh4T5D
That’s it. Diagnostics have kidnapped the PR team so they haven’t got time to publish any RNS on AVA6000 clinical trial progress 🤣🤣🤣
Thought i would try email questions to Avacta CEO . Status of two weekly study & Spotlight Series -Episode 3 etc - So far no reply .
-------------
Meantime LD continue to boost products :
"This month is coeliac awareness month."
https://www.linkedin.com/feed/update/urn:li:activity:7197222958333837312/
1,705 followers1,705 followers
19h • 19 hours ago
This month is coeliac awareness month.
With a prevalence of 1 in 100, hundreds of thousands of people in the UK have coeliac disease, but only 36% have received a diagnosis.
It is therefore estimated that 500,000 people in the UK are living with undiagnosed coeliac disease. Coping with unexplained health problems without diagnosis can have significant effects on both mental and physical health.
NICE guideline NG20 states; when healthcare professionals request serological tests to investigate suspected coeliac disease in young people and adults laboratories should test for IgA tissue transglutaminase (tTG) as the first choice. With the HOB BioCLIA 500 or BioCLIA 6500 testing for IgA (or IgG) anti-tTG is quick and easy, with a large range of further autoimmune assays also available on the platforms.
Contact your local Launch representative or go to our website for further information.
https://lnkd.in/esUcttq
https://www.coeliac.org.uk
https://lnkd.in/d329Vfg
Good afternoon - LD in action
"
Launch Diagnostics LimitedLaunch Diagnostics Limited
1,706 followers1,706 followers
1h • 1 hour ago
The team from Launch are ready to welcome you at hashtag#cvn2024 taking place at Austin Court in Birmingham today and tomorrow.
We look forward to speaking with existing contacts and making new connections, come and see us to discuss the solutions available from Launch Diagnostics Ltd for your service."
https://www.linkedin.com/feed/update/urn:li:activity:7198626699314352128/
https://clinicalvirology.org/events/
LD sponsers with the big boys
https://view.officeapps.live.com/op/view.aspx?src=https%3A%2F%2Fclinicalvirology.org%2Fwp-content%2Fuploads%2F2023%2F12%2FClinical-Virology-Network-May-2024-Programme.docx&wdOrigin=BROWSELINK